Serious Adverse Events, Cardiovascular Health Impact Stroke Risk in RA

Comorbidities and Differential Diagnosis
Comorbidities and Differential Diagnosis
Serious adverse events, especially those requiring hospitalization, may indicate an elevated risk of stroke.

WASHINGTON, DC – Serious adverse events (SAEs) that require hospitalization significantly impact stroke risk in patients with rheumatoid arthritis (RA). The findings were presented at the 2016 American College of Rheumatology Annual Meeting in Washington, DC.

It’s understood that patients with RA are at an increased risk for experiencing infections, hospitalizations, and cardiovascular events such as stroke; however it is not known how precedent SAEs or cardiovascular treatment impacts stroke incidence.

In this study, researchers led by Yvette Meissner, of the German Rheumatism Research Center in Berlin, Germany conducted a nested case-control study using participants in the German biologics register RABBIT. The register includes RA patients on a conventional synthetic or biologic DMARD after ≥1 csDMARD failure. Demographics, comorbidities, clinical status, disease activity, RA treatment, and SAEs are recorded every 6 months. Cases with incident non-hemorrhagic stroke were included in the analysis, with 2 controls per case.

Overall, cases and controls were older and had more cardiovascular risk factors than those remaining in the register. Treatment of RA, comorbid osteoporosis, and diabetes was treated similarly across cases and controls; however cardiovascular diseases were treated significantly less frequently in cases.

Related Articles

After adjustments, the researchers found that patients with treated cardiovascular diseases had only a moderately elevated risk for stroke (hazard ratio (HR) 1.41; 95% CI, 0.66-3.01) compared with patients with untreated cardiovascular disease, who showed a significantly elevated risk for stroke (HR 3.10; 95% CI, 1.41-6.79). However, patients with precedent SAEs had a 2.5-fold greater cumulative incidence of stroke compared to those with no history of SAEs, with risk greatest immediately following the SAE.

Notably, treatment with TNF inhibitors and other bDMARDS was not linked to stroke risk (HR 0.9; 95% CI, 0.6-1.4 and HR 0.7; 95% CI, 0.4-1.2, respectively).

“These results strengthen the need for better CV management in RA patients,” the authors concluded.

The authors report no relevant disclosures.

For more coverage of ACR 2016, click through to our sister site Rheumatology Advisor


Meissner Y, Richter A, Kekow J, et al. The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events. Presented at: the 2016 American College of Rheumatology/ Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting. November 11-16, 2016; Washington, DC. Abstract #1993